SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 410 participants.

Also called NCT06955260

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 410 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06955260
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06955260. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-29 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
Acronym
EMPA-HEART-3
Condition
Congenital Heart Disease
Intervention (Drug)
Empagliflozin 10 mg
Intervention (Other)
Placebo
Lead sponsor
Subodh Verma (class: other)
Collaborator
Boehringer Ingelheim (class: industry)
Collaborator
Applied Health Research Centre (class: other)

Record details

Record id
cardio:ct-nct06955260
Content hash
25bbaaefcd9a22dc21a5f1c014b6aa86e33b67c7db089750a0171420054a9a54